[A cohort study of hepatitis B virus carriers progressing to chronic hepatitis in Jiangsu province, 2012-2014]

L G Zhu1, J Jiang1, C Song2

  • 1Major Project Executive Office, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.

Insights

Hepatitis B virus (HBV) carriers in Jiangsu showed a 21.0/100 person-years incidence of chronic hepatitis B. HBV DNA levels significantly influenced progression, highlighting the need for regular monitoring in carriers.

Area of Science:

  • Hepatology
  • Epidemiology
  • Virology

Background:

  • Hepatitis B virus (HBV) carriers represent a significant public health concern.
  • Understanding the progression of HBV carriers to chronic hepatitis B is crucial for effective management.

Purpose of the Study:

  • To investigate the epidemiological characteristics of HBV carriers progressing to chronic hepatitis B in Jiangsu province.
  • To identify key influencing factors, including demographics and viral markers, associated with this progression.
  • To provide evidence-based recommendations for the regular management of HBV carriers.

Main Methods:

  • A cohort study was conducted from 2012 to 2014 involving HBV carriers in Jiangsu.
  • Cox regression analyses were employed to assess the association between HBV carrier factors and chronic hepatitis B incidence.
  • Demographic data, Hepatitis B e-antigen (HBeAg) levels, and HBV DNA detection results were analyzed.

Main Results:

  • A total of 4,069 HBV carriers were initially surveyed, with 1,444 progressing to chronic hepatitis B by 2014, yielding an incidence rate of 21.0/100 person-years.
  • Hepatitis B virus DNA level was identified as a significant influencing factor (P<0.05) for chronic hepatitis B development, alongside gender.
  • Among HBeAg-positive carriers who progressed, 40.7% experienced HBeAg seroconversion, while 1.7% of HBeAg-negative carriers showed HBeAg reversion.

Conclusions:

  • Over one-fifth of HBV carriers in the study area developed chronic hepatitis B within the observation period.
  • Regular monitoring of alanine aminotransferase (ALT), HBV DNA levels, and abdominal ultrasound examinations is recommended for early detection of chronic hepatitis B in carriers.